Results 181 to 190 of about 97,918 (260)

Cardiac MRI-guided therapeutics in ischemic cardiomyopathy: impact on heart-team consensus and outcomes. [PDF]

Front Cardiovasc Med
Karumuri DR, Rathinasamy J, Sakthivel AA, Ragireddy HR, Suliankatchi Abdulkader R, Shah AH, Ramalingam V, Siddhan RM, Salahuddin S, Jacob B, Parasuraman SK, Rajakaruna C, Rajendran R, Bhumana S, Wilson A, Kovvuri HL, Saravana Kumar P, Shanmugasundaram S, Sankaran R, Balasubramaniyan JV, Balakrishnan VK, Murthy JSN, Sadagopan T, Senguttuvan NB.   +23 more
europepmc   +1 more source

Cardiovascular toxicity from immune checkpoint inhibitor therapy: an inflammatory continuum

British Journal of Pharmacology, EarlyView.
Immune checkpoint inhibitor (ICI) therapy has markedly improved outcomes in advanced malignancies but has also revealed a distinct spectrum of cardiovascular immune‐related adverse events. Myocarditis represents the most severe manifestation, while non‐inflammatory left ventricular dysfunction and vascular inflammation have emerged as additional ...
Fabrice Reyes, Florian Buehning, Tobias Lerchner, Julia Vogel, Raluca I. Mincu, Matthias Totzeck, Tienush Rassaf, Lars Michel   +7 more
wiley   +1 more source

Evaluation of Cardiac Function After Stereotactic Body Radiation Therapy for Lung Tumors: Results of the Prospective Explorative Heart-Lung Study. [PDF]

Adv Radiat Oncol
Hoeksema WF, Belderbos J, Dieleman EMT, van Doorn-Wink K, de Bruin-Bon HACM, van der Ree MH, Visser J, Hopman LHGA, van Kesteren Z, Postema PG, Planken RN, Sonke JJ, Stam B.   +12 more
europepmc   +1 more source

Refining the treatment of immune checkpoint inhibitor–associated myocarditis: Challenges, innovations and rechallenge considerations

British Journal of Pharmacology, EarlyView.
Immune checkpoint inhibitor (ICI)‐associated myocarditis has emerged as a severe and clinically complex immune‐related toxicity that poses significant challenges for therapeutic decision‐making in routine cardio‐oncological care. High‐dose corticosteroids remain the first‐line therapy, yet their timing, dosage and tapering require careful clinical ...
Raluca I. Mincu, Lisa Zimmer, Dimitra Vlachopoulou, Elias Haj‐Yehia, Julia Hoffmann, Lars Michel, Elisabeth Livingstone, Dirk Schadendorf, Alpaslan Tasdogan, Matthias Totzeck, Tienush Rassaf   +10 more
wiley   +1 more source

Cardiac Magnetic Resonance Findings and NT-proBNP in Heart Failure with Reduced Ejection Fraction. [PDF]

Tomography
Memis KB, Doğan İ, Şahin D, Gulmez AO, Özer E, Kantarci M.   +5 more
europepmc   +1 more source

Arrhythmias associated with immune checkpoint inhibitor therapy—A clinical perspective

British Journal of Pharmacology, EarlyView.
Immune checkpoint inhibitors (ICIs) have transformed cancer therapy but are associated with a growing spectrum of cardiovascular immune‐related adverse events. Among these, arrhythmias represent a rare yet potentially life‐threatening complication. ICI‐induced arrhythmias encompass a wide clinical spectrum, including atrial arrhythmias, conduction ...
Dong Wang, Melanie Ricke‐Hoch, David Duncker, Johann Bauersachs, Dominik Berliner   +4 more
wiley   +1 more source

Donut Morphology of Cardiac Amyloidosis: A Glazed Over Diagnosis. [PDF]

JACC Case Rep
Aggarwal P, Alpert C, Davies D.
europepmc   +1 more source

MCL‐1 inhibition triggers a largely reversible cardiac stress signature in a humanised mouse model

British Journal of Pharmacology, EarlyView.
Abstract Background and Purpose Myeloid cell leukaemia‐1 (MCL‐1) is an essential anti‐apoptotic protein and a promising therapeutic target in oncology. Early clinical studies of MCL‐1 inhibitors reported unexpected elevations in cardiac troponin, raising concerns about potential cardiotoxicity.
Markus B. Heckmann, Zsanett Papdi, Nils J. Strauch, Daniel Finke, Marc‐Steffen Raab, Antje Blank, Norbert Frey, Lorenz H. Lehmann   +7 more
wiley   +1 more source

Multimodality assessment of right ventricular-pulmonary arterial coupling and pulmonary artery compliance in youth with pulmonary arterial hypertension: A pilot study. [PDF]

JHLT Open
Raj S, Khan B, Raj V, Pulagam VR, Das BB.   +4 more
europepmc   +1 more source

Treatment‐Free Remission in Chronic Myeloid Leukemia: Toward Precision and Personalized Approaches to Functional Cure

Cancer Science, EarlyView.
Immune surveillance of residual leukemic stem cells after tyrosine kinase inhibitor discontinuation involves coordinated NK‐cell, CTL, Treg, pDC, and neutrophil activity that predicts treatment‐free remission, while exhausted CTLs and Treg expansion predict relapse in chronic myeloid leukemia.
Hiroshi Ureshino, Shinya Kimura
wiley   +1 more source